Internet marketing of neuroproducts: New practices and healthcare policy challenges

Cambridge Quarterly of Healthcare Ethics

Volumn 16, Issue 2, 2007, Pages 181-194

  Racine, Eric ^a   Van Der Loos, H Z Adriaan ^a   Illes, Judy ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ADVERTIZING; DRUG INDUSTRY; ECONOMICS; ETHICS; HEALTH CARE POLICY; HUMAN; INTERNET; MARKETING; METHODOLOGY; NEUROLOGIC DISEASE; ORGANIZATION AND MANAGEMENT; REVIEW; STATISTICS;

ADVERTISING; DRUG INDUSTRY; HEALTH POLICY; HUMANS; INTERNET; MARKETING; NERVOUS SYSTEM DISEASES; PHARMACEUTICAL PREPARATIONS;

EID: 33947398026     PISSN: 09631801     EISSN: 14692147     Source Type: Journal    
DOI: 10.1017/S096318010707020X     Document Type: Review

References (50)

1. Ma J, Stafford RS, Cockburn IM, Finkelstein SN. A statistical analysis of the magnitude and composition of drug promotion in the United States in 1998. Clinical Therapeutics 2003;25:1503-17.
2. Gahart MT, Duhamel LM, Dievler A, Price R. Examining the PDA's oversight of direct-to-consumer advertising. Health Affairs 2003;Suppl Web Exclusives:W3-120-3.
3. See note 1, Ma et al. 2003; see note 2, Gahart et al. 2003; Hollon MF. Direct-to-consumer advertising: A haphazard approach to health promotion. JAMA 2005;293:2030-3.
4. Styra R. The Internet's impact on the practice of psychiatry. Canadian Journal of Psychiatry 2004;49:5-11;
5. Hollon MF. Direct-to-consumer marketing of prescription drugs: A current perspective for neurologists and psychiatrists. CNS Drugs 2004;18:69-77.
6. Weissman JS, Blumenthal D, Silk AJ, Newman M, Zapert K, Leitman R, et al. Physicians report on patient encounters involving direct-to-consumer advertising. Health Affairs 2004;Suppl Web Exclusives:W4-219-33.
7. Berger M, Wagner TH., Baker LC. Internet use and stigmatized illness. Social Science and Medicine 2005;61:621-7.
8. See note 4, Hollon 2004; see note 5, Weissman et al. 2004.
9. Illes J, Kann D, Karetsky K, Letourneau P, Raffin TA, Schraedley-Desmond P, et al. Advertising, patient decision making, and self-referral for computed tomography and magnetic resonance imaging. Archives of Internal Medicine 2004;164:2415-9.
10. New York State Task Force on Life & the Law. Dietary Supplements: Balancing Consumer Choice & Safety. Albany, NY: Department of Health; 2005.
11. Katsnelson A. Big biotech embraces direct-to-consumer advertising. Nature Biotechnology 2005;23:1.193.
12. Gollust SE, Hull SC, Wilfond BS. Limitations of direct-to-consumer advertising for clinical genetic testing. JAMA 2002;288:1762-7;
13. McCabe LL, McCabe ERB. Direct-to-consumer genetic testing: Access and marketing. Genetic Medicine 2004;6:58-9;
14. Centers for Disease Control and Prevention. Genetic testing for breast and ovarian cancer susceptibility: Evaluating direct-to-consumer marketing-Atlanta, Denver, Raleigh-Durham, and Seattle. Morbidity and Mortality Weekly Report 2004;53:603-6;
15. Editorial. Unapproved tests on a chip. Nature 2005;438:71.
16. See note 11, Gollust et al. 2002.
17. NDCHealth. 2004. RxList, The top 300 prescriptions for 2004 by number of US prescriptions dispensed; c2005 (cited Dec 8). Available at: http://www.rxlist.com/top200.htm.
18. See note 11, Gollust et al. 2002; Illes J, Fan E, Koenig B, Raffin TA, Kann D, Atlas SW. Self-referred whole-body CT imaging: Current implications for health care consumers. Radiology 2003;228:346-51.
19. See note 14, Illes et al. 2003.
20. See note 11, Gollust et al. 2002; see note 14, Illes et al. 2003; Bell RA, Kravitz RL, Wilkes MS. Direct-to-consumer prescription drug advertising, 1989-1998. A content analysis of conditions, targets, inducements, and appeals. The Journal of Family Practice 2000;49:329-35;
21. Cho MK, Arruda M, Holtzman NA. Educational material about genetic tests: Does it provide key information for patients and practitioners? American Journal of Medical Genetics 1997;73:314-20.
22. See note 2, Gahart et al. 2003; U.S. General Accounting Office. Prescription Drugs: PDA Oversight of Direct-to-Consumer Advertising has Limitations (CAO-03177). Report to Congressional Requesters. Washington, D.C.: U.S. General Accounting Office; 2002; Food and Drug Administration. C.F.R. 21 vol. 4, Part 202. Washington, D.C.: U.S. Government Printing Office, 2001:72-81.
23. See note 11, Gollust et al. 2002; see note 14, Illes et al. 2004.
24. See note 16, Cho et al. 1997.
25. See note 17, U.S. General Accounting Office 2002.
26. Three top neuropharmaceuticals from the RXList had no identifiable Web site and were discarded in favor of the next mostly prescribed pharmaceutical with a Web site on the RXList.
27. See note 17, U.S. Food and Drug Administration 2001.
28. Noah BA. Dietary supplement regulation in flux. American Journal of Law & Medicine 2005;31:147-53.
29. See note 23, Noah 2005.
30. Herb A. Off-label drug use. Annual Meeting. American Society for Bioethics and the Human-ities, Washington, D.C.; 2005.
31. Waack KE, Ernst ME, Graber MA. Informational content of official pharmaceutical industry web sites about treatments for erectile dysfunction. The Annals of Pharmacotherapy 2004;38:2029-34.
32. See note 6, Berger et al. 2005.
33. See note 9, New York State Task Force on Life & the Law 2005.
34. Wolfe SM. Direct-to-consumer advertising-education or emotion promotion. New England Journal of Medicine 2002;346:524-6.
35. Farrell J. The ethical implications of direct-to-consumer pharmaceutical advertising. Philosophy & Public Policy Quarterly 2003;23:20-3.
36. Mintzes B, Barer ML, Kravitz RL, Bassett K, Lexchin J, Kazanjian A, et al. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. Canadian Medical Association Journal 2003;169:405-12;
37. Gilbody S, Wilson P, Watt I. Benefits and harms of direct to consumer advertising: A systematic review. Quality & Safety in Health Care 2005;14:246-50;
38. Hansen RA, Shaheen NJ, Schommer JC. Factors influencing the shift of patients from one proton pump inhibitor to another: The effect of direct-to-consumer advertising. Clinical Therapeutics 2005;27:1478-87;
39. Mouchawar J, Laurion S, Ritzwoller DP, Ellis J, Kulchak-Rahm A, Hensley-Alford S. Assessing controversial direct-to-consumer advertising for hereditary breast cancer testing: Reactions from women and their physicians in a managed care organization. American Journal of Managed Care 2005;11:601-8.
40. Donohue JM, Berndt ER, Rosenthal M, Epstein AM, Frank RG. Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression. Medical Care 2004;42:11.76-85.
41. Murray E, Lo B, Pollack L, Donelan K, Lee K. Direct-to-consumer advertising: Public perceptions of its effects on health behaviors, health care, and the doctor-patient relationship. The Journal of the American Board of Family Practice 2004;17:6-18.
42. World Health Organization. The World Health Report 2001. Mental Health: New Understanding, New Hope. Geneva, Switzerland: World Health Organization; 2001.
43. Kravitz RL, Epstein RM, Feldman MD, Franz CE, Azari R, Wilkes MS, et al. Influence of patients' requests for direct-to-consumer advertised antidepressants: A randomized controlled trial. JAMA 2005;293:1995-2002.
44. See note 33, Murray et al. 2004.
45. See note 4, Hollon 2004.
46. See note 11, Centers for Disease Control and Prevention 2004.
47. Herculano-Houzel S. Do you know your brain? A survey on public neuroscience literacy at the closing of the decade of the brain. The Neuroscientist 2002;8:98-110.
48. Racine E, Bar-Ilan O, Illes J. fMRI in the public eye. Nature Reviews Neuroscience 2005;6:159-64.
49. The Ethics, Law and Humanities Committee of the American Academy of Neurology. Practice advisory: Participation of neurologists in direct-to-consumer advertising. Neurology 2001;59:995-6.
50. Cassell EJ. The Schiavo case: A medical perspective. Hastings Center Report 2005;35:22-3.